• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 18, 2017

View Archived Issues

Notch belted again as tarextumab bites dust; Oncomed tries 'TGIT' traction with early bids

"These are tough-to-treat cancers and we knew they were tough-to-treat cancers going in," Oncomed Pharmaceuticals Inc. CEO Paul Hastings said, but results "all the way back to our xenograft data, as well as our phase Ib data, gave us every indication that these were indications which we should go forward with," and the company "did the right thing" by pursuing them, he said. Read More

In the clinic

Ampliphi Biosciences Corp., of San Diego, said the FDA provided positive feedback on the company's previously submitted detailed development proposal to start a phase II trial with its bacteriophage cocktail AB-SA01 for the treatment of antibiotic-resistant Staphylococcus aureus infections in patients with chronic rhinosinusitis. Read More

Biopharma gets its groove back as Q1 approval of NMEs grows

It looks as though the biopharmaceutical industry is back on track to make up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's green light, the fewest number for five years. In the first quarter of this year, 12 NMEs were approved, outperforming comparable periods since 2013. Read More

High-dose chemo helps cancer vaccine

A dendritic cell vaccine against a viral antigen induced long-term survival in three out of 11 treated glioblastoma patients, scientists reported in the April 15, 2017, issue of Clinical Cancer Research. Read More

Amorchem spinout Mperia advancing CD36 drug-ligand in dry AMD

When going after macrophages, "in my view, you play directly with the immune system," said Maxime Ranger, president and CEO of 2016 startup Mperia Therapeutics Inc., which is advancing macrophage-targeting immunotherapies based on the CD36 scavenger receptor for diseases involving chronic inflammation such as dry age-related macular degeneration (AMD) and atherosclerosis. Read More

Cansino lands $65M to fund global vaccine development, new plant

SHANGHAI – Chinese vaccine developer Cansino Inc., of Tianjin, has received $65 million in a financing round led by Future Industry Investment Fund to hasten the development of its later-stage vaccines and get a new vaccine plant up-and-running. Read More

Financings

Kalytera Therapeutics Inc., of Vancouver, British Columbia, said it applied for a $5 million grant from the Israel Innovation Authority (IIA) to fund development of its portfolio of cannabidiol (CBD) prodrugs including: K-1012, indicated for acute respiratory distress syndrome; K-1022, indicated for ulcerative colitis; K-1032, indicated for acne vulgaris; and K-1052, being studied as an inducible nitric oxide synthase inhibitor, indicated for sepsis-associated renal failure and severe traumatic brain injury. Read More

Other news to note

Amag Pharmaceuticals Inc., of Waltham, Mass., reported that it has submitted a supplemental new drug application to the FDA for Makena (Hydroxyprogesterone Caproate Injection) subcutaneous auto-injector, its drug-device product. Amag developed the new product with Antares Pharma Inc., of Ewing, N.J. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe